CDT Equity Taps Co-Founder James Bligh as CEO to Drive Growth Strategy
Event summary
- James Bligh, co-founder of Conduit Pharmaceuticals (now CDT Equity), appointed CEO effective September 1, 2026.
- Dr. Andrew Regan transitions to CEO of Sarborg Limited, a quantum signature intelligence firm in which CDT holds a 22% stake.
- CDT has recently strengthened its balance sheet, reduced operating costs, and completed strategic investments including Sarborg stake acquisition.
- Bligh brings over a decade of experience in public markets, corporate finance, and M&A transactions.
The big picture
CDT Equity's appointment of James Bligh as CEO underscores its shift from a biopharmaceutical developer to a broader investment platform leveraging AI and quantum computing. The move comes amid a period of strategic restructuring, including balance sheet strengthening and targeted investments, reflecting a trend among specialty healthcare firms to diversify through high-growth adjacencies. The 22% stake in Sarborg positions CDT at the intersection of biotech and quantum intelligence, a niche with significant but unproven market potential.
What we're watching
- Portfolio Performance
- Whether CDT's 22% stake in Sarborg will deliver expected returns as the quantum signature intelligence market evolves.
- Operational Efficiency
- The pace at which CDT can sustain cost reductions while pursuing high-potential science-driven opportunities.
- Leadership Impact
- How James Bligh's M&A and corporate finance experience will shape CDT's next phase of growth and value creation.
Related topics